← Leaderboards
Claudio Maldonado
University Of Louisville
$2,468,554
Attributed
$4,551,825
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $974.5K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,551,825 · 6
By mechanism
R44$2,900,095 · 2
R42$963,666 · 1
K01$340,274 · 1
R43$224,812 · 1
R41$122,978 · 1
Top collaborators
- Philip Bauer5 shared
- Xian-Liang Tang3 shared
- Leila Gobejishvili2 shared
Most similar at University Of Louisville
Same institution · by research overlap
- Xian-Liang Tang$2,255,729
Others in their field
Top investigators on “Ischemia”
- Judith S Hochman · New York University School Of Medicine$110,228,771
- Peter Scott Heeger · Case Western Reserve University$37,264,795
- Katherine M Detre · University Of Pittsburgh At Pittsburgh$32,928,566
- Mary McGrae McDermott · Northwestern University$31,833,655
- Junichi Sadoshima · Rutgers Biomedical And Health Sciences$28,880,313
- Roberto Bolli · University Of Louisville$27,383,989
Research focus
IschemiaVesicleBaseCellsInflammationLipidsAdverse EffectsTreatment EfficacyLifeSafetyDrug KineticsReperfusion InjuryReperfusion TherapyToxic EffectNovel TherapeuticsInjuryPerfusionHeartEndothelial CellsCell MembraneIn VivoCause Of DeathBlood FlowEdema
Grant awards (11)
A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction$736,042
R44 · FY2019 · HL
A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction$749,712
R44 · FY2018 · HL
Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease$749,725
R44 · FY2016 · AA
A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction$224,812
R43 · FY2016 · HL
Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease$664,616
R44 · FY2015 · AA
New anti-complement therapy to reduce reperfusion injury: Phase II$464,776
R42 · FY2009 · HL · contact PI
New anti-complement therapy to reduce reperfusion injury: Phase II$498,890
R42 · FY2008 · HL · contact PI
New anti-complement therapy to reduce reperfusion injury$122,978
R41 · FY2005 · HL
PKC AND ISCHEMIC PRECONDITIONING OF MUSCLE$115,831
K01 · FY2002 · HL
PKC AND ISCHEMIC PRECONDITIONING OF MUSCLE$113,401
K01 · FY2001 · HL
PKC AND ISCHEMIC PRECONDITIONING OF MUSCLE$111,042
K01 · FY2000 · HL